Table of Contents Author Guidelines Submit a Manuscript
Anemia
Volume 2012, Article ID 172104, 9 pages
http://dx.doi.org/10.1155/2012/172104
Clinical Study

Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials

1Wake Gastroenterology and Wake Research Associates, Raleigh, NC 27612, USA
2Luitpold Pharmaceuticals, Inc., Norristown, PA 19403, USA
3WebbWrites, LLC, Durham, NC 27705, USA
4Department of Pathology, Albert Einstein College of Medicine, NY 10461, USA

Received 11 April 2012; Accepted 23 June 2012

Academic Editor: Aurelio Maggio

Copyright © 2012 Charles F. Barish et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Killip, J. M. Bennett, and M. D. Chambers, “Iron deficiency anemia,” American Family Physician, vol. 75, no. 5, pp. 671–678, 2007. View at Google Scholar · View at Scopus
  2. J. Umbreit, “Iron deficiency: a concise review,” American Journal of Hematology, vol. 78, no. 3, pp. 225–231, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. P. Gisbert and F. Gomollón, “Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease,” American Journal of Gastroenterology, vol. 103, no. 5, pp. 1299–1307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. D. Haas and T. T. Brownlie, “Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship,” Journal of Nutrition, vol. 131, no. 2, pp. 676S–690S, 2001. View at Google Scholar · View at Scopus
  5. S. Horton and C. Levin, “Commentary on ‘evidence that iron deficiency anemia causes reduced work capacity’,” Journal of Nutrition, vol. 131, no. 2, pp. 691S–696S, 2001. View at Google Scholar · View at Scopus
  6. J. P. Gisbert, F. Bermejo, R. Pajares et al., “Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement,” Inflammatory Bowel Diseases, vol. 15, no. 10, pp. 1485–1491, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. D. H. Henry, “The role of intravenous iron in cancer-related anemia,” Oncology, vol. 20, no. 8, pp. 21–24, 2006. View at Google Scholar · View at Scopus
  8. A. F. Goddard, M. W. James, A. S. McIntyre, and B. B. Scott, “Guidelines for the management of iron deficiency anaemia,” Gut, vol. 60, pp. 309–1316, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. “KDOQI, National Kidney Foundation: II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults,” American Journal of Kidney Diseases, vol. 47, no. 5, supplement 3, pp. S16–S85, 2006.
  10. L. Gotloib, D. Silverberg, R. Fudin, and A. Shostak, “Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron,” Journal of Nephrology, vol. 19, no. 2, pp. 161–167, 2006. View at Google Scholar · View at Scopus
  11. W. Y. Qunibi, “The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review,” Arzneimittel-Forschung, vol. 60, no. 6 a, pp. 399–412, 2010. View at Google Scholar · View at Scopus
  12. M. H. Rosner and M. Auerbach, “Ferumoxytol for the treatment of iron deficiency,” Expert Review of Hematology, vol. 4, no. 4, pp. 399–406, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Santosh, P. Podaralla, and B. Miller, “Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol,” NDT Plus, vol. 3, no. 4, pp. 341–342, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. K. A. Lyseng-Williamson and G. M. Keating, “Ferric carboxymaltose: a review of its use in iron-deficiency anaemia,” Drugs, vol. 69, no. 6, pp. 739–756, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Geisser and J. Banké-Bochita, “Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia,” Arzneimittel-Forschung, vol. 60, no. 6 a, pp. 362–372, 2010. View at Google Scholar · View at Scopus
  16. P. Geisser and V. Rumyantsev, “Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder,” Arzneimittel-Forschung, vol. 60, no. 6 a, pp. 373–385, 2010. View at Google Scholar · View at Scopus
  17. F. Funk, P. Ryle, C. Canclini, S. Neiser, and P. Geisser, “The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose,” Arzneimittel-Forschung, vol. 60, no. 6 a, pp. 345–353, 2010. View at Google Scholar · View at Scopus
  18. R. A. Moore, H. Gaskell, P. Rose, and J. Allan4, “Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data,” BMC Blood Disorders, vol. 11, no. 1, article 4, 2011. View at Google Scholar
  19. S. Kulnigg, S. Stoinov, V. Simanenkov et al., “A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial,” American Journal of Gastroenterology, vol. 103, no. 5, pp. 1182–1192, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Y. Qunibi, C. Martinez, M. Smith, J. Benjamin, A. Mangione, and S. D. Roger, “A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis- dependent chronic kidney disease patients,” Nephrology Dialysis Transplantation, vol. 26, no. 5, pp. 1599–1607, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Tagboto, L. Cropper, J. Turner, and K. Pugh-Clarke, “The efficicacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients,” Journal of Renal Care, vol. 35, no. 1, pp. 18–23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. D. B. Van Wyck, A. Mangione, J. Morrison, P. E. Hadley, J. A. Jehle, and L. T. Goodnough, “Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial,” Transfusion, vol. 49, no. 12, pp. 2719–2728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. D. B. Van Wyck, M. G. Martens, M. H. Seid, J. B. Baker, and A. Mangione, “Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial,” Obstetrics and Gynecology, vol. 110, no. 2 I, pp. 267–278, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. S. D. Anker, J. C. Colet, G. Filippatos et al., “Ferric carboxymaltose in patients with heart failure and iron deficiency,” The New England Journal of Medicine, vol. 361, no. 25, pp. 2436–2448, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. P. W. F. Wilson, R. B. D'Agostino, D. Levy, A. M. Belanger, H. Silbershatz, and W. B. Kannel, “Prediction of coronary heart disease using risk factor categories,” Circulation, vol. 97, no. 18, pp. 1837–1847, 1998. View at Google Scholar · View at Scopus
  26. A. C. Arroliga, K. K. Guntupalli, J. S. Beaver, W. Langholff, K. Marino, and K. Kelly, “Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss,” Critical Care Medicine, vol. 37, no. 4, pp. 1299–1307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Shimizu, Y. Tada, M. Yamauchi et al., “Hypophosphatemia induced by intravenous administration of saccharated ferric oxide. Another form of FGF23-related hypophosphatemia,” Bone, vol. 45, no. 4, pp. 814–816, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. B. J. Schouten, P. J. Hunt, J. H. Livesey, C. M. Frampton, and S. G. Soule, “FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 7, pp. 2332–2337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Y. Mani, G. Nseir, J. P. Venetz, and M. Pascual, “Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient,” Transplantation, vol. 90, no. 7, pp. 804–805, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. A. C. Grimmelt, C. D. Cohen, T. Fehr, A. L. Serra, and R. P. Wüthrich, “Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients,” Clinical Nephrology, vol. 71, no. 2, pp. 125–129, 2009. View at Google Scholar · View at Scopus